NCT07701161 · RECRUITING
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
This study is testing whether a home finger-stick blood device called Tasso can measure p-tau217 as accurately as a traditional blood draw done in a clinic. P-tau217 is a protein in the blood that researchers use as a marker of Alzheimer's-related brain changes. This is a validation study, not a treatment trial — it is asking whether the home device gives reliable readings, not testing any drug or therapy.
You may qualify if
- AD Amyloid PET/CSF confirmed, healthy control, or amyloid-negative non-AD cognitive impairment Age 40-90 Able to complete Tasso and venipuncture collection Caregiver consent/assistance available if needed
You're excluded if
- Uncontrolled systemic conditions Recent surgery/hospitalization (3 months) Other dementia drug trial (2 months) Pregnancy Prior Donanemab or Lecanemab use
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-07-14